A Plus Biotechnology Co (TPE:6918) Research & Development: NT$46.6 Mil (TTM As of Dec. 2025)


TPE:6918 A Plus Biotechnology Co Ltd TPE:6918
71 GF Score
Price NT$74.20
GF Value NT$87.15
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is A Plus Biotechnology Co Research & Development?

A Plus Biotechnology Co TPE:6918 -0.13% 71 Research & Development is NT$46.6 Mil as of Dec. 2025. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. A Plus Biotechnology Co's Research & Development for the three months ended in Dec. 2025 was NT$11.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$46.6 Mil.

A Plus Biotechnology Co  (TPE:6918) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

A Plus Biotechnology Co Research & Development Related Terms

A Plus Biotechnology Co Research & Development Historical Data

* Premium members only.

The historical data trend for A Plus Biotechnology Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co Research & Development Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 63.08 77.00 59.54 53.34 46.64

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.03 12.31 11.07 11.84 11.42
TPE:6918
71GF Score
A Plus Biotechnology Co Ltd TPE:6918
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

A Plus Biotechnology Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$46.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$46.6 Mil mean?
A Plus Biotechnology Co (TPE:6918) has a Research & Development of NT$46.6 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on A Plus Biotechnology Co and its competitors.
Is A Plus Biotechnology Co's Research & Development too high?
A Plus Biotechnology Co's current Research & Development is NT$46.6 Mil. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Research & Development compare to ABT and SYK?
A Plus Biotechnology Co's Research & Development of NT$46.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on A Plus Biotechnology Co and its competitors. A Plus Biotechnology Co's current Research & Development is NT$46.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.20 — trading 14.9% below its estimated fair value. The current Research & Development is NT$46.6 Mil. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Research & Development is NT$46.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?

Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued. The current stock price of NT$74.20 is trading 14.9% below its estimated GF Value™ of NT$87.15. GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.

Key valuation signals for TPE:6918:

  • Research & Development: NT$46.6 Mil
  • GF Value™: NT$87.15 vs. price of NT$74.20 (14.9% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

A Plus Biotechnology Co Business Description

Address No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score

Get the complete analysis for TPE:6918

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.20
Price
NT$87.15
GF Value